Numerous clinical trials evaluate conditions including soft tissue sarcoma, multiple sclerosis, colorectal cancer survivor rehabilitation, and post-traumatic ankle osteoarthritis across Phase 1 through Phase 4 and non-interventional designs. Diverse sponsors—spanning academic centers such as M.D. Anderson Cancer Center, the University of Iowa, and the University of Toronto, alongside pharmaceutical companies GlaxoSmithKline and Daiichi Sankyo—report recruitment statuses ranging from active, recruiting, and completed to not yet recruiting and withdrawn.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03138161 | RECRUITING | Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma |
Sarcoma Oncology Research Center, LLC |
2017-04-13 | PHASE1; PHASE2 |
| NCT07281508 | RECRUITING | Cisplatin-related Hearing Loss |
The Netherlands Cancer Institute |
2025-08-14 | PHASE3 |
| NCT03582800 | RECRUITING | Systemic Sclerosis; Dermatomyositis; iPPSD2 |
University Hospital, Limoges |
2020-01-06 | PHASE2 |
| NCT06672822 | RECRUITING | Systemic Sclerosis (SSc); Dermatomyositis; Mixed Connective Tissue Disease (MCTD); Calcinosis |
Robyn T. Domsic, MD, MPH |
2025-03-17 | PHASE2 |
| NCT07407582 | RECRUITING | Solid Tumor Malignancies; Testicular Cancer; Head and Neck Cancer; Thoracic Cancer |
University of Arizona |
2026-05-18 | PHASE1; PHASE2 |
| NCT07049848 | RECRUITING | Soft Tissue Sarcoma |
M.D. Anderson Cancer Center |
2025-09-11 | PHASE2 |
| NCT03112980 | ACTIVE_NOT_RECRUITING | Aortic Valve Stenosis |
Universitätsklinikum Hamburg-Eppendorf |
2017-05-10 | |
| NCT07650838 | NOT_YET_RECRUITING | Soft Tissue Sarcoma (STS) |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2026-08-01 | PHASE2 |
| NCT03819985 | ACTIVE_NOT_RECRUITING | Resectable Soft Tissue Sarcoma; Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 |
M.D. Anderson Cancer Center |
2018-12-17 | PHASE2 |
| NCT06116578 | WITHDRAWN | Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-01-01 | PHASE2 |
| NCT04166006 | RECRUITING | Head Neck Tumors; Neuroendocrine Tumors; Soft Tissue Sarcoma; Rare Cancer; Vaccination |
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS |
2019-12-12 | PHASE2 |
| NCT07430709 | NOT_YET_RECRUITING | Pulmonary Function Testing |
Technopulm |
2026-03-05 | |
| NCT05111964 | RECRUITING | Soft Tissue Sarcoma; Desmoid Tumors |
Oxford University Hospitals NHS Trust |
2021-12-10 | |
| NCT05944913 | RECRUITING | Soft Tissue Sarcoma |
Centre Leon Berard |
2023-08-03 | |
| NCT05597917 | RECRUITING | Soft Tissue Sarcoma |
Universität Münster |
2021-10-26 | PHASE3 |
| NCT05813327 | TERMINATED | Soft Tissue Sarcoma; Sts; Sarcoma,Soft Tissue |
Washington University School of Medicine |
2024-03-14 | PHASE1 |
| NCT05823740 | COMPLETED | Cancer; Malignant Neoplasm |
UNC Lineberger Comprehensive Cancer Center |
2023-05-01 | |
| NCT05518526 | UNKNOWN | Soft Tissue Sarcoma; Pulmonary Metastasis |
Maria Sklodowska-Curie National Research Institute of Oncology |
2022-08-23 | PHASE1; PHASE2 |
| NCT05761054 | RECRUITING | Soft Tissue Sarcoma |
Azienda Ospedaliero-Universitaria Careggi |
2022-07-19 | |
| NCT06479252 | UNKNOWN | Chronic Lung Disease |
West Park Healthcare Centre |
2024-06-22 | |
| NCT04829188 | COMPLETED | Sepsis; Pneumonia; Lower Resp Tract Infection; Covid19 |
University of Pittsburgh |
2021-03-30 | |
| NCT05209347 | Withdrawn | Ankle Fractures|Post-traumatic Osteoarthritis|Osteoarthritis Ankle |
University of Iowa |
2024-12 | Not Applicable |
| NCT02910895 | UNKNOWN | Soft Tissue Sarcoma; Xenograft Model; 2D/3D Cell Cultures |
The Netherlands Cancer Institute |
2017-09-09 | |
| NCT05956990 | Not yet recruiting | Colorectal Cancer Survivor|Rehabilitation|Quality of Life |
Qu Shen|The First Affiliated Hospital of Xiamen University|Xiamen University |
2024-07-01 | Not Applicable |
| NCT05945134 | UNKNOWN | Stroke |
National Yang Ming Chiao Tung University |
2023-07-15 | |
| NCT05957289 | Not yet recruiting | Rehabilitation|Colorectal Cancer Survivor|Quality of Life|Pilot Study |
Qu Shen|The First Affiliated Hospital of Xiamen University|Xiamen University |
2024-06-01 | Not Applicable |
| NCT06245135 | Not yet recruiting | Mobility Limitation |
University of Toronto|University Health Network Toronto|March of Dimes Canada|Heart and Stroke Foundation of Canada|University of Alberta|University of Manitoba|Bruyere Research Institute |
2024-06 | Not Applicable |
| NCT05471661 | COMPLETED | Opportunistic Fungal Infection; Opportunistic Viral Infection; Bone Marrow Transplant Infection |
George Papanicolaou Hospital |
2021-05-22 | PHASE1; PHASE2 |
| NCT06374108 | Not yet recruiting | Multiple Sclerosis |
University of Aarhus|Aarhus University Hospital|University of Copenhagen |
2024-05-01 | Not Applicable |
| NCT04317547 | COMPLETED | Drive; Adolescent Behavior; Risk Behavior |
Ginger Yang |
2020-09-28 | |
| NCT05277285 | UNKNOWN | COVID-19; Virus Diseases; Corona Virus Infection |
Hellenic Institute for the Study of Sepsis |
2022-04-01 | PHASE2 |
| NCT03217266 | COMPLETED | Resectable Soft Tissue Sarcoma; Soft Tissue Sarcoma |
National Cancer Institute (NCI) |
2018-06-20 | PHASE1 |
| NCT04541355 | COMPLETED | Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Locally Advanced Head and Neck Squamous Cell Carcinoma; Locally Advanced Hypopharyngeal Squamous Cell Carcinoma; Locally Advanced Laryngeal Squamous Cell Carcinoma; Locally Advanced Oral Cavity Squamous Cell Carcinoma; Locally Advanced Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IV Hypopharyngeal Carcinoma AJCC v8; Stage IV Laryngeal Cancer AJCC v8; Stage IV Lip and Oral Cavity Cancer AJCC v8; Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVC Hypopharyngeal Carcinoma AJCC v8; Stage IVC Laryngeal Cancer AJCC v8; Stage IVC Lip and Oral Cavity Cancer AJCC v8; Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8 |
Hyunseok Kang, MD |
2020-10-14 | PHASE2 |
| NCT05597995 | UNKNOWN | Epidermoid Cyst |
Goldman, Butterwick, Fitzpatrick and Groff |
2022-11-01 | PHASE2 |
| NCT00075387 | UNKNOWN | Malignant Glioma |
OHSU Knight Cancer Institute |
2003-03-07 | PHASE2 |
| NCT03232931 | COMPLETED | Preterm Infant |
Emory University |
2018-10-29 | |
| NCT05469191 | COMPLETED | Quality of Life; Quality Muscle; Arquitecture Muscle |
Universidad de Granada |
2022-08-08 | |
| NCT04342377 | COMPLETED | Lung Cancer; Non Small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II |
St. Joseph's Healthcare Hamilton |
2020-11-30 | PHASE3 |
| NCT02899364 | UNKNOWN | Myocardial Infarction; Heart Failure |
University Medical Center Groningen |
2018-07-20 | PHASE2 |
| NCT04058548 | COMPLETED | Cystic Fibrosis |
Boston Children's Hospital |
2019-09-05 | |
| NCT03126591 | COMPLETED | Soft Tissue Sarcoma |
Eli Lilly and Company |
2017-07-03 | PHASE1 |
| NCT04579055 | COMPLETED | COPD; Chronic Obstructive Pulmonary Disease |
Thomas Riegler |
2020-09-16 | |
| NCT03859349 | COMPLETED | Non Small Cell Lung Cancer |
St. Joseph's Healthcare Hamilton |
2019-05-06 | |
| NCT03042819 | COMPLETED | Soft Tissue Sarcoma |
University Health Network, Toronto |
2017-05-16 | PHASE1 |
| NCT03177031 | COMPLETED | Continuous Ambulatory Peritoneal Dialysis |
Penang Hospital, Malaysia |
2017-06-13 | |
| NCT03089476 | WITHDRAWN | Atopic Dermatitis; Eczema; Food Allergy |
National Jewish Health |
2017-09-30 | |
| NCT02636725 | COMPLETED | Alveolar Soft Part Sarcoma; Soft Tissue Sarcomas |
Jonathan Trent, MD, PhD |
2016-04-19 | PHASE2 |
| NCT02367651 | WITHDRAWN | Sarcoma, Soft Tissue |
GlaxoSmithKline |
2015-06 | PHASE2 |
| NCT04211519 | COMPLETED | Endodontic Disease; Endodontic Inflammation |
Nuh Naci Yazgan University |
2017-09-01 | |
| NCT02066675 | COMPLETED | Metastatic and Locally Advanced Soft Tissue Tumor Patients Unfit to Receive; Standard Chemotherapy |
Italian Sarcoma Group |
2014-02 | PHASE2 |
| NCT00484341 | COMPLETED | Metastatic Adult Soft Tissue Sarcoma |
AGC Biologics S.p.A. |
2010-10 | PHASE2 |
| NCT01418001 | TERMINATED | Sarcoma; Leiomyosarcoma; Malignant Peripheral Nerve Sheath Tumor; Malignant Fibrous; Histiocytoma/Undifferentiated Pleomorphic Sarcoma |
Memorial Sloan Kettering Cancer Center |
2011-08 | PHASE1; PHASE2 |
| NCT01653587 | COMPLETED | Acute Coronary Syndrome |
Irmandade Santa Casa Misericórdia Marília |
2012-07 | PHASE4 |
| NCT02010437 | WITHDRAWN | Superficial Venous Insufficiency, Varicose Veins |
Hull University Teaching Hospitals NHS Trust |
2014-01 | PHASE4 |
| NCT01918904 | WITHDRAWN | Calcinosis Cutis |
Loyola University |
2013-09 | PHASE2 |
| NCT01369641 | TERMINATED | Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2011-08-24 | |
| NCT00276302 | COMPLETED | Gastrointestinal Stromal Tumors; Soft Tissue Sarcomas |
Infinity Pharmaceuticals, Inc. |
2005-12 | PHASE1 |
| NCT00640614 | COMPLETED | Contact Dermatitis |
Allerderm |
2008-04 | PHASE3 |
| NCT00439413 | COMPLETED | Nicotine Dependence |
National Institute on Drug Abuse (NIDA) |
2007-06 | PHASE2 |
| NCT00064220 | COMPLETED | Sarcoma |
Daiichi Sankyo |
2003-04 | PHASE2 |
| NCT00013585 | COMPLETED | Cognition Disorders; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 |
(data from https://clinicaltrials.gov, updated on 2025-02-24)
Check the
Staurosporine (STS)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Staurosporine (STS) Mechanism of Action: Protein Kinase Inhibition in Mammalian Cell Research
- Staurosporine (STS) Working Concentration | Cell Culture | Treatment
- Staurosporine (STS) Solubility in DMSO
- Staurosporine (STS) Stock Solution
- Staurosporine (STS) Storage
- Staurosporine (STS) Stability
- Staurosporine (STS) Combination Database
- Staurosporine (STS) Molecular Weight
- Staurosporine (STS) SMILES
- Staurosporine (STS) CAS Number
- Staurosporine (STS) Chemical Structure (2D and 3D)
- Staurosporine (STS) IC50 for Cell-based and Cell-free Assays
- Staurosporine (STS) Cell Signaling Technology (9953)? Try a better option.
- Staurosporine (STS) Sigma (S4400)? Try a better option.
- Staurosporine (STS) Cayman (81590)? Try a better option.
- Staurosporine (STS) MedChemExpress (HY-15141)? Try a better option.
- Staurosporine (STS) Tocris (TB1285-RMU)? Try a better option.
- Staurosporine (STS) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.